ImpediMed Ltd (ASX:IPD) has entered into a three-year joint development agreement with Mayo Clinic in the U.S. to explore additional uses for its body fluid status monitoring technology.
ImpediMed’s device uses bioimpedance spectroscopy (BIS) technology to assess body fluid changes, which can help health care providers better detect and manage chronic disease in patients.
The company has the first medical device with FDA clearance in the U.S. to clinically assess secondary unilateral lymphedema, which is the swelling caused by a lymphatic system blockage.
Mayo Clinic and ImpediMed will jointly develop new product solutions to address other diseases where fluid burden and body composition are important, potentially including cardiology and nephrology.
The Mayo Clinic is one of the largest non-profit medical practice and medical research groups in the world.
The joint development agreement builds on ImpediMed’s strong relationship with Mayo Clinic. In May 2016, the organizations entered a five-year strategic agreement for clinical research.
In March, ImpediMed closed a successful private placement of $75 million.
ImpediMed has signed up with 17 new cancer centres in the U.S. in the March quarter and is targeting 50 of the top 500 cancer centres in CY2016.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.